What is the recommended treatment for a 28‑year‑old Black female with plaque psoriasis?

Treatment for a 28-Year-Old Black Female with Plaque Psoriasis

For a 28-year-old Black female with moderate-to-severe plaque psoriasis, biologic therapy with adalimumab, ustekinumab, or an IL-17 inhibitor (ixekizumab, secukinumab, bimekizumab) is recommended as first-line systemic treatment, with the specific choice depending on disease severity, affected body sites, presence of psoriatic arthritis, and patient preference for dosing frequency. 1

Treatment Algorithm by Disease Severity

Mild Psoriasis (BSA <3%)

• Start with topical therapy: High-potency corticosteroids (class 1-2) for up to 4 weeks on thick plaques, combined with vitamin D analogues 2
• Class 1 corticosteroids (clobetasol, halobetasol) achieve 58-92% efficacy rates at 2 weeks 2
• For scalp involvement: topical corticosteroid solutions (class 1-7) as initial and maintenance treatment 2

Moderate-to-Severe Psoriasis (BSA ≥3% or high-impact sites)

First-Line Biologic Options (all Grade A recommendations):

1. Adalimumab 1

   • Dosing: 80 mg initial dose (two 40-mg injections), then 40 mg one week later, followed by 40 mg every 2 weeks
   • Some patients require 40 mg weekly for better control
   • PASI 75 achieved in 71% at week 16 (vs 7% placebo)
   • PASI 90 achieved in 45% at week 16
   • Particularly effective for palmoplantar, nail, and scalp psoriasis

2. Ustekinumab (IL-12/23 inhibitor) 1

   • Dosing: 45 mg if ≤100 kg OR 90 mg if >100 kg, given at weeks 0 and 4, then every 12 weeks
   • PASI 75 achieved in 67-76% at week 12 depending on dose
   • Longest dosing interval (every 12 weeks) improves adherence
   • Can intensify to every 8 weeks if inadequate response

3. IL-17 Inhibitors (highest efficacy based on recent evidence) 3, 4

   • Ixekizumab: RR 27.35 for PASI 90 vs placebo (high-certainty evidence) 3
   • Bimekizumab: RR 27.86 for PASI 90 vs placebo (high-certainty evidence) 3
   • Secukinumab: Established efficacy with extensive safety data
   • Note: Monitor for mucocutaneous candidiasis and avoid in inflammatory bowel disease 5

4. IL-23 Inhibitors (newer agents with durable responses) 5, 3

   • Risankizumab: RR 26.16 for PASI 90 vs placebo (high-certainty evidence) 3
   • Guselkumab: Durable responses with longer dosing intervals
   • Advantage: Less frequent dosing (every 8-12 weeks after loading)

Second-Line Options:

• Methotrexate 6

  • Dosing: 7.5-25 mg weekly (oral or subcutaneous)
  • Less effective than adalimumab and infliximab for cutaneous psoriasis 6
  • Requires folic acid supplementation (1 mg daily) 6
  • Monitor liver function every 3-6 months 6
  • Consider when cost/access limits biologic use

• Etanercept 1

  • Dosing: 50 mg twice weekly for 12 weeks, then 50 mg weekly
  • Lower efficacy than newer biologics but established safety profile

Special Considerations for This Patient

Age and Reproductive Potential

• Critical: Methotrexate is absolutely contraindicated if pregnancy is planned within 3 months 6
• Biologics (adalimumab, ustekinumab, IL-17/IL-23 inhibitors) are safer options for women of childbearing age
• Discuss contraception and family planning before initiating any systemic therapy

Race-Specific Considerations

• No specific dosing adjustments needed based on race
• Black patients may have higher rates of certain comorbidities (hypertension, metabolic syndrome) that should be screened before starting therapy

Site-Specific Treatment

For Scalp Involvement:

• Adalimumab (Grade A) or etanercept (Grade A) as monotherapy 1
• Ustekinumab has limited evidence (Grade C) 1
• Combine with topical clobetasol solution for rapid initial control 7

For Nail Involvement:

• Adalimumab (Grade A) or ustekinumab (Grade B) 1
• Nail improvement takes 16-40 weeks 1

For Palmoplantar Involvement:

• Adalimumab (Grade A) or ustekinumab (Grade B) 1
• Consider acitretin 25 mg daily if biologics unavailable 7

Combination Therapy Options

To augment efficacy, biologics can be combined with:

• High-potency topical corticosteroids ± vitamin D analogues (Grade A-B for adalimumab, Grade C for ustekinumab) 1
• Methotrexate (Grade B for adalimumab/ustekinumab) 1
• Narrowband UVB phototherapy (Grade B) 1

Monitoring and Safety

Baseline screening before biologics:

• Tuberculosis testing (PPD or QuantiFERON)
• Hepatitis B and C serology
• Complete blood count
• Pregnancy test

Common pitfalls to avoid:

• Do not use infliximab without concomitant methotrexate due to high immunogenicity risk 1
• Do not abruptly stop topical corticosteroids (risk of rebound) 2
• Do not exceed 4 weeks of continuous high-potency topical corticosteroids on face/intertriginous areas 2

Treatment Selection Framework

Choose adalimumab if:

• Patient needs proven efficacy across all psoriasis subtypes
• Prefers self-administered subcutaneous injection every 2 weeks
• Has concurrent psoriatic arthritis (Grade A indication) 1

Choose ustekinumab if:

• Patient prioritizes longest dosing interval (every 12 weeks)
• Prefers established long-term safety profile
• Has concurrent psoriatic arthritis (Grade A indication) 1

Choose IL-17 or IL-23 inhibitor if:

• Patient requires highest efficacy for complete skin clearance 3
• Rapid response is priority (IL-17 inhibitors) 5
• Patient has no history of inflammatory bowel disease or recurrent candidiasis

Choose methotrexate only if:

• Biologics are not accessible due to cost/insurance
• Short-term disease control needed before transitioning to biologics
• Patient accepts lower efficacy and monitoring requirements 6